Protective efficacy of vitamin B\textsubscript{12} combined with far-infrared radiation on radiation-induced skin damage in the treatment of pelvic tumours

Qin Ge MD, Cen-ming Yu MD, Jing Cai MD, Chun-xia Chu MD, Guo-dong Xie MD, Ji-Zhong Zhao MD

OBJECTIVE: To determine the protective efficacy of vitamin B\textsubscript{12} combined with far-infrared radiation on radiation-induced skin damage in the treatment of acute and chronic pelvic tumours.

METHODS: One hundred patients requiring radiation therapy were randomly assigned into two groups: 50 patients were assigned to the control group and received usual care; the 50 patients assigned to the experimental group were, in addition to usual care, given vitamin B\textsubscript{12} (0.25 mg/mL) injections to radiation-sensitive perineal skin and subsequently treated with far-infrared radiation beginning the first day of radiotherapy. Far-infrared radiation treatment was performed at a light distance of 40 cm at a temperature of 28°C to 32°C for 25 min twice per day.

RESULTS: The incidence of acute skin reactions in the two groups was statistically different (P<0.05). The incidences of grades I, II, III and IV radiation-induced skin damage in the experimental group were 60.0%, 30.0%, 10.0% and 0%, respectively; in contrast, the incidences in the control group were 26.0%, 54.0%, 18.0% and 2.0%, respectively. Grades II to IV skin reactions in the experimental group were remarkably less severe than those of the control group. When a radiation treatment dose of <40 Gy was used, the incidences of acute radiation-induced dermatitis in the control and experimental groups were 66% and 34%, respectively (P<0.05).

CONCLUSION: Vitamin B\textsubscript{12} combined with far-infrared radiation had a markedly protective effect on acute radiation-induced skin damage in the treatment of pelvic tumours. Moreover, the treatment improved patient quality of life and was clinically valuable.

Key Words: Far-infrared; Radiation dermatitis; Pelvic tumours; Radiation therapy; Vitamin B\textsubscript{12}

Treatment

All patients were initially treated with radiation. To determine the precise location and extent of the tumour, patients were positioned prone on a table with their head stabilized, and underwent 16-slice spiral computed tomography (CT) scan using a slice thickness of 5 mm. Data were transferred to the Pinnacle3 8.0 program design system; an experienced radiologist and two physicians calculated gross tumour volume (GTV) based on the CT images of tumour and lymph node metastasis. The GTV was used to determine clinical target volume (CTV), which included lymphatic drainage area. Planning target volume was then calculated based on GTV and CTV; approximately 0.5 cm to 1.0 cm was added to the margins to account for setup errors, visceral activity and other factors, and to avoid organs at risk, including the bladder, the lower small intestine and the femoral head. Patients were treated using three-dimensional conformal radiation or intensity modulated radiation therapy, using 6 MV x-rays and a noncoplanar five-field arrangement. The doses corresponding to 95% of planning target volume were 50 Gy to 76 Gy per 25 to 38 fractions (1.8 Gy/fraction to 2 Gy/fraction; five fractions per week).

A total of 50 patients in the control group received conventional care. Detailed explanations regarding the efficacy of radiation and its importance were provided to patients before radiotherapy. Patients were advised to wear soft, loose-fitting, absorbent clothing to avoid friction; use a warm, soft cloth to wash, and avoid scrubbing the skin with hot water and bath soap; and avoid the use of iodized oil, alcohol and other disinfectants, and irritating ointments. Antibacterial agents were applied to the skin after it had been cleaned.

The patients in the experimental group were treated with vitamin B\textsubscript{12} injections (0.25 mg/mL) and subsequently underwent far-infrared

Department of Radiation Oncology, Nantong Tumor Hospital, Nantong, People's Republic of China
Correspondence: Dr Chun-xia Chu, Jiangsu Nantong, Nantong Tumor Hospital, Nantong 226361, People's Republic of China.
Telephone 13813606819, e-mail cxc5194666@sina.com

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact support@pulsus.com
**TABLE 1**
Clinical characteristics of patients in the experimental and control groups

| Characteristic                  | Group       | Experimental | Control | P  | \(\chi^2\) |
|--------------------------------|-------------|--------------|---------|----|------------|
| Sex                            |             | Male         | 39      | 38 | 0.055      | 0.614 |
|                                |             | Female       | 11      | 12 |             |       |
| Age, years                     |             | ≤60          | 34      | 33 | 0.044      | 0.834 |
|                                |             | >60          | 16      | 17 |             |       |
| Tumour Node Metastasis staging |             | II           | 38      | 39 | 0.055      | 0.814 |
|                                |             | III          | 12      | 11 |             |       |
| Lymph node metastasis          |             | No           | 29      | 31 | 0.018      | 0.894 |
|                                |             | Yes          | 21      | 19 |             |       |
| Degree of differentiation      |             | High         | 24      | 23 | 0.039      | 0.843 |
|                                |             | Low          | 26      | 27 |             |       |

Data presented as n unless otherwise indicated

**TABLE 2**
Incidence of acute skin injury postradiation

| Grade of skin damage | Group        | 0 | I | II | III | IV |
|----------------------|--------------|---|---|----|-----|----|
|                      | Experimental | 0 | 30 | 15 | 30  | 0  |
|                      | Control      | 0 | 13 | 27 | 54  | 9  |

Data presented as n (%). *0* – no skin change; grade I – follicular dark erythema or hair loss, dry desquamation and decreased sweating; grade II – tenderness or new-onset erythema, flaky moist desquamation, moderate edema; grade III – outside skin folds fusion, moist desquamation, pitting edema; and grade IV – ulcers, bleeding and necrosis. \(\chi^2=9.57, P<0.05\)

Acute radiation-induced skin damage, also known as acute radiation dermatitis, is a common complication of radiotherapy. The incidence and severity of acute radiation dermatitis is related to radiation wavelength, the irradiated volume and interpatient differences, among many other factors. Its pathogenesis is believed to result from dysregulation of DNA synthesis and differentiation, leading to a series of skin reactions and, ultimately, damage. As reported, several drugs, including antibiotics and hormones, have been used for the treatment of acute radiation-induced skin damage. Unfortunately, the results have been disappointing. The incidence of acute skin damage following exposure to radiation has been reported to be as high as 90% (2). In recent years, many attempts have been made to alleviate the severity of damage. Suping et al (3) treated 24 patients who experienced skin damage following irradiation using a topical agent (MEBO, Sekanjalo Healthcare, South Africa), while Zhimei (4) treated 38 patients with special dressings. Li et al (5) and Wu et al (6) used JUC, and antimicrobial spray and dressing, and peptide to prevent acute radiation dermatitis in 29 and 120 cases, respectively. Therefore, effective methods of ameliorating radiation-induced skin damage have practical significance for clinical care.

**DISCUSSION**

Acute radiation-induced skin damage, also known as acute radiation dermatitis, is a common complication of radiotherapy. The incidence and severity of acute radiation dermatitis is related to radiation wavelength, the irradiated volume and interpatient differences, among many other factors. Its pathogenesis is believed to result from dysregulation of DNA synthesis and differentiation, leading to a series of skin reactions and, ultimately, damage. As reported, several drugs, including antibiotics and hormones, have been used for the treatment of acute radiation-induced skin damage. Unfortunately, the results have been disappointing. The incidence of acute skin damage following exposure to radiation has been reported to be as high as 90% (2). In recent years, many attempts have been made to alleviate the severity of damage. Suping et al (3) treated 24 patients who experienced skin damage following irradiation using a topical agent (MEBO, Sekanjalo Healthcare, South Africa), while Zhimei (4) treated 38 patients with special dressings. Li et al (5) and Wu et al (6) used JUC, and antimicrobial spray and dressing, and peptide to prevent acute radiation dermatitis in 29 and 120 cases, respectively. Therefore, effective methods of ameliorating radiation-induced skin damage have practical significance for clinical care.

Vitamin B₁₂ is produced by the liver and is involved in several biochemical metabolic reactions. It promotes the repair of damaged skin mucous membranes and vascular endothelial cells, reduces spasm and occlusion of blood vessels, improves local blood flow and prevents the deterioration of wound infection. In addition, it reduces the excitability of pain fibres C and Aδ, leading to an analgesic effect (7,8).

Suping et al (3) treated 24 patients who experienced skin damage following irradiation using a topical agent (MEBO, Sekanjalo Healthcare, South Africa), while Zhimei (4) treated 38 patients with special dressings. Li et al (5) and Wu et al (6) used JUC, and antimicrobial spray and dressing, and peptide to prevent acute radiation dermatitis in 29 and 120 cases, respectively. Therefore, effective methods of ameliorating radiation-induced skin damage have practical significance for clinical care.

Vitamin B₁₂ is produced by the liver and is involved in several biochemical metabolic reactions. It promotes the repair of damaged skin mucous membranes and vascular endothelial cells, reduces spasm and occlusion of blood vessels, improves local blood flow and prevents the deterioration of wound infection. In addition, it reduces the excitability of pain fibres C and Aδ, leading to an analgesic effect (7,8).

Light at the far-infrared end of the visible spectrum has wavelengths of 0.76 μm to 1000 μm. Its use in the medical field began abroad in the 1920s, and did not appear in China until the 1950s. Far-infrared radiation is useful for the dilation of blood vessels and restoring blood flow, and for repair and adjustment of other biological systems that cause imbalances in the body. It plays an important role in
Protective efficacy of vitamin $B_{12}$ in radiation-induced dermatitis

In vitro, vitamin $B_{12}$ has been shown to promote cellular DNA synthesis, enhance cellular metabolism and maintain cell membrane function in animal experiments (11). Far-infrared radiation has been used widely in burn care for many years except radiation-induced skin damage (12-16). Although radiation-induced skin damage is unique, its physiological characteristics are similar to burn injury.

Currently, effective measures to prevent or delay the occurrence of radiation dermatitis and reduce the extent of injury are lacking. The prevention of wound infection depends on the development of new technologies and methods of care. Both vitamin $B_{12}$ and far-infrared have biological effects of repair in damaged skin and mucous membrane cells, but using them in combination has an additive effect, thus providing enhanced protection from the effects of radiation. The results of the present study showed that grade II, III or IV radiation-induced skin damage was significantly more serious, with a longer average healing time, in the control group compared with the experimental group, suggesting that the combination of vitamin $B_{12}$ injections supplemented with far-infrared radiation mitigates the severity of skin injury postradiation. It has been shown that erythema develops when skin is irradiated with as little as 5 Gy, and epithelial exfoliation and ulceration (wet reaction) occur with doses of approximately 20 Gy to 40 Gy, often resulting in serious prolonged healing of ulcers (17). To date, there have been no effective measures or drugs to treat skin damage induced by radiation. When mild skin reactions occur, patients are encouraged to adhere to radiotherapy. When severe reactions occur, patients are given anti-inflammatory treatment, debridement, dressings and other symptomatic treatment, with skin wound healing time of up to two to four weeks, which can seriously affect quality of life. Moreover, because of interruption to radiation therapy, tumour control time is reduced, further decreasing the survival rate of patients (18).

We showed that higher doses of radiation increased the frequency and severity of acute radiation-induced skin damage. When the radiation dose was >40 Gy, more patients in the experimental group developed skin damage. In contrast, at doses <40 Gy, radiation-induced skin damage was more prevalent in the control group. The difference was statistically significant, indicating that the combination of vitamin $B_{12}$ injections and far-infrared radiation therapy prolonged the length of acute radiation-induced skin injury.

ACKNOWLEDGEMENT: This research was funded by the 2013_H513917 Social Undertakings Technology Innovation and Demonstration Program (mentoring program).

DISCLOSURES: The authors have no financial disclosures or conflicts of interest to declare.

REFERENCES
1. Troiti A, Colevas AD, Setser A, et al. CTC AE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
2. Li Jianhua, Cheng Quye, Shen Xiaoyun, et al. Five butter in the prevention of radiation dermatitis patient care application. Chinese J Pract Nurs 2009;24:61-2.
3. Suping W, Deng B. Clinical MEBO radiodermatitis. J Clin Nurs 2006;5:35-6.
4. Zhimei W. Observation much love dressing treatment of acute radiation dermatitis skin 38 cases efficacy. Pract Oncol 2002;5:348-9.
5. Li Y, Lin G, Cheng H, et al. JUC prevention of acute radiation dermatitis and 29 cases Observation. Chinese J Skin Dis 2006;5:285.
6. Wu D, Li X, Su L, et al. Preliminary clinical observation prevention of acute radiation skin and mucous reactions. By Franciscan complex. Chinese J Clin Oncol Rehabil 2002;1:62-3.
7. Dai Z. Clinical Antimicrobial Agents from Beijing: People's Health Publishing House, 1998.
8. Troiti A. Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys 2000;47:1-12.
9. Gao BY, Lu Y, Yu J. Vitamin $B_{12}$ treatment of cervical cancer patients with mixed effects of acute radiation skin damage observed. J Modern Oncol 2006;16:813-5.
10. Chen C, Chen X, Chen J, et al. Vitamin B12 mixed solution treatment of radioactive moist dermatitis. J Nurs 2002;19:20-1.
11. Lv X, Li M. Far infrared biological effects and clinical application in tissue repair. Clin Rehab Tissue Engrn Res China 2009;46:9147-50.
12. Yamashita H. Development of CO$_2$ water with or activation of mitochondrial metabolism. Technol Med 2005;6:868-72.
13. Udagawa Y, Ishigame H, Nagasawa H. Effects of hydroxyapatite in combination with far-infrared rays on spontaneous mammary tumorigenesis in SHN mice. Am J Chin Med 2002;30:495-505.
14. Wang B, Yang Y. Material, such as efficient infrared radiation therapy (HISP) development and application. Tianjin Medical University 1995;2:7-9.
15. Zhang J. On the far infrared health care. Soviet Technol Achieve Bulletin 2001;11:3-4.
16. Yan X, Wu Y, Zhu W. Infrared comparative study of burn depth diagnosis and clinical judgment. Chinese J Burns 2004;1:44.
17. Song Y, Puxu Y, Song X. MEBO treatment of acute radiation dermatitis degree II clinical observation. Chinese J Burns 1997;5:57-8.
18. Luosong X, Tanguy X, Guo K. 1,446 patients with nasopharyngeal carcinoma compared with piecewise continuous radiation therapy. J Radiation Oncol 1994;3:78-80.

Curr Res Integr Med Vol 1 No 1 Spring 2015 7